Access the full text.
Sign up today, get DeepDyve free for 14 days.
Karschnia (2022)
vdac158Neurooncol Adv, 4
A. Dono, Sonali Mitra, Mauli Shah, Takeshi Takayasu, Jay-Jiguang Zhu, N. Tandon, C. Patel, Y. Esquenazi, L. Ballester (2021)
PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastomaJournal of Neuro-Oncology, 153
A. Insilla, A. Proietti, N. Borrelli, E. Macerola, C. Niccoli, P. Vitti, P. Miccoli, F. Basolo (2017)
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer casesOncology Letters, 15
M. Giordano, E. Macerola, L. Boldrini, R. Giannini, A. Servadio, G. Alí, F. Melfi, M. Lucchi, P. Bertoglio, A. Mussi, G. Fontanini (2015)
TERT Promoter Mutations and Tert Expression in Early-Stage (T1N0M0) Non-Small Cell Lung Cancer (NSCLC)Experimental pathology, 5
D. Louis, A. Perry, P. Wesseling, D. Brat, I. Cree, D. Figarella-Branger, C. Hawkins, H. Ng, S. Pfister, G. Reifenberger, R. Soffietti, A. Deimling, D. Ellison (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.Neuro-oncology
Yuanqing Yan, Takeshi Takayasu, Gabriella Hines, A. Dono, S. Hsu, Jay-Jiguang Zhu, R. Riascos-Castaneda, A. Kamali, M. Bhattacharjee, A. Blanco, N. Tandon, Dong Kim, L. Ballester, and Esquenazi (2020)
Landscape of Genomic Alterations in IDH Wild-Type Glioblastoma Identifies PI3K as a Favorable Prognostic Factor.JCO precision oncology, 4
Insilla (2018)
2763Oncol Lett, 15
Hai Yan, D. Parsons, Geng-lin Jin, R. McLendon, B. Rasheed, Weishi Yuan, I. Kos, I. Batinic-Haberle, Siân Jones, G. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, Kenneth Kinzler, V. Velculescu, B. Vogelstein, D. Bigner (2009)
IDH1 and IDH2 mutations in gliomas.The New England journal of medicine, 360 8
François Hafezi, Danielle Bercoff (2020)
The Solo Play of TERT Promoter MutationsCells, 9
Y. Kanda (2012)
Investigation of the freely available easy-to-use software ‘EZR' for medical statisticsBone Marrow Transplantation, 48
Marta Dratwa, B. Wysoczańska, P. Łacina, T. Kubik, K. Bogunia-Kubik (2020)
TERT—Regulation and Roles in Cancer FormationFrontiers in Immunology, 11
J. Eckel-Passow, D. Lachance, A. Molinaro, K. Walsh, P. Decker, H. Sicotte, M. Pekmezci, T. Rice, M. Kosel, I. Smirnov, G. Sarkar, Alissa Caron, T. Kollmeyer, Corinne Praska, A. Chada, C. Halder, H. Hansen, L. McCoy, P. Bracci, Roxanne Marshall, S. Zheng, G. Reis, A. Pico, B. O'neill, J. Buckner, C. Giannini, J. Huse, A. Perry, T. Tihan, M. Berger, Susan Chang, M. Prados, J. Wiemels, J. Wiencke, M. Wrensch, R. Jenkins (2015)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.The New England journal of medicine, 372 26
Dono (2021)
vdab050Neurooncol Adv, 3
A. Dono, Emily Wang, V. Lopez-Rivera, Arvind Ramesh, N. Tandon, L. Ballester, Y. Esquenazi (2020)
Molecular characteristics and clinical features of multifocal glioblastomaJournal of Neuro-Oncology, 148
D. Brat, K. Aldape, H. Colman, E. Holland, D. Louis, R. Jenkins, B. Kleinschmidt-DeMasters, A. Perry, G. Reifenberger, R. Stupp, A. Deimling, M. Weller (2018)
cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”Acta Neuropathologica, 136
A. Dono, P. Zhu, S. Zorofchian, Takeshi Takayasu, M. Quezado, A. Rios, Astin Powers, Y. Esquenazi, L. Ballester (2020)
Variable expression of CXCR4 in molecular subtypes of infiltrating gliomas.Clinical neuropathology
Emilia Hugdahl, M. Kalvenes, M. Mannelqvist, Rita Ladstein, L. Akslen (2017)
Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanomaBritish Journal of Cancer, 118
D. Louis, A. Perry, G. Reifenberger, A. Deimling, D. Figarella-Branger, W. Cavenee, H. Ohgaki, O. Wiestler, P. Kleihues, D. Ellison (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 131
G. Frampton, Alex Fichtenholtz, G. Otto, Kai Wang, S. Downing, Jié He, Michael Schnall-Levin, Jared White, Eric Sanford, Peter An, James Sun, F. Juhn, K. Brennan, K. Iwanik, Ashley Maillet, J. Buell, Emily White, M. Zhao, S. Balasubramanian, S. Terzic, Tina Richards, Vera Banning, Lazaro Garcia, Kristen Mahoney, Z. Zwirko, Amy Donahue, H. Beltran, J. Mosquera, M. Rubin, S. Dogan, C. Hedvat, M. Berger, L. Pusztai, M. Lechner, C. Boshoff, M. Jarosz, C. Vietz, A. Parker, V. Miller, J. Ross, J. Curran, M. Cronin, P. Stephens, D. Lipson, R. Yelensky (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 31
Robert Bell, H. Rube, Ana Xavier-Magalhães, B. Costa, A. Mancini, Jun Song, J. Costello (2016)
Understanding TERT Promoter Mutations: A Common Path to ImmortalityMolecular Cancer Research, 14
Kenta Masui, T. Komori, Y. Kato, K. Masutomi, K. Ichimura, S. Ogasawara, M. Kaneko, H. Oki, Hiroyoshi Suzuki, M. Nitta, T. Maruyama, Y. Muragaki, T. Kawamata, T. Sawada, N. Shibata (2018)
Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific AntibodyBioMed Research International, 2018
A. Tallet, Jessie Nault, A. Renier, I. Hysi, Françoise Galateau-Sallé, A. Cazes, M. Copin, Paul Hofman, Pascal Andujar, F. Pimpec-Barthes, J. Zucman‐Rossi, M. Jaurand, Didier Jean (2014)
Overexpression and promoter mutation of the TERT gene in malignant pleural mesotheliomaOncogene, 33
A. Siraj, Rong Bu, K. Iqbal, S. Parvathareddy, Nabil Siraj, Sarah Siraj, M. Diaz, D. Rala, Allianah Benito, M. Sabido, Maha Al‐Rasheed, Khadija Obaisi, Wael Al-Haqawi, Ingrid Victoria, Wafaa Balawy, M. Abedalthagafi, S. Wakil, D. Ajarim, S. Mohammed, T. Alhussain, A. Tulbah, I. Al-Badawi, F. Al-Dayel, K. Al-Kuraya (2020)
Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.Genomics
Dratwa (2020)
1Front Immunol, 11
P. Karschnia, Jacob Young, A. Dono, L. Häni, S. Juenger, T. Sciortino, Francesco Bruno, N. Teske, R. Morshed, Alexander Haddad, Yalan Zhang, Sophia Stoecklein, M. Vogelbaum, J. Beck, N. Tandon, S. Hervey-Jumper, A. Molinaro, R. Rudà, L. Bello, O. Schnell, Y. Esquenazi, M. Ruge, S. Grau, M. Bent, M. Weller, M. Berger, Susan Chang, J. Tonn (2022)
TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect groupNeuro-Oncology Advances, 4
A. Dono, Arvind Ramesh, Emily Wang, Mauli Shah, N. Tandon, L. Ballester, Y. Esquenazi (2021)
The role of RB1 alteration and 4q12 amplification in IDH-WT glioblastomaNeuro-oncology Advances, 3
Johan Paulsson, Anton Olander, F. Haglund, J. Zedenius, C. Juhlin (2018)
TERT Immunohistochemistry Is a Poor Predictor of TERT Promoter Mutations and Gene Expression in Follicular Thyroid CarcinomaEndocrine Pathology, 29
T. Gaspar, Anabela Sá, J. Lopes, M. Sobrinho-Simões, P. Soares, J. Vinagre (2018)
Telomere Maintenance Mechanisms in CancerGenes, 9
M. Muzza, C. Colombo, S. Rossi, D. Tosi, V. Cirello, M. Perrino, S. Leo, E. Magnani, E. Pignatti, Beatrice Vigo, M. Simoni, G. Bulfamante, L. Vicentini, L. Fugazzola (2015)
Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localizationMolecular and Cellular Endocrinology, 399
M. Wood, A. Halfpenny, S. Moore (2019)
Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entitiesDiagnostic Pathology, 14
C. Brennan, R. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S. Salama, Siyuan Zheng, D. Chakravarty, J. Sanborn, Samuel Berman, R. Beroukhim, Brady Bernard, Chang-Jiun Wu, G. Genovese, I. Shmulevich, J. Barnholtz-Sloan, L. Zou, Rahulsimham Vegesna, S. Shukla, G. Ciriello, W. Yung, Wei Zhang, C. Sougnez, T. Mikkelsen, K. Aldape, D. Bigner, Erwin Meir, M. Prados, A. Sloan, K. Black, J. Eschbacher, G. Finocchiaro, W. Friedman, D. Andrews, A. Guha, M. Iacocca, B. O'neill, G. Foltz, J. Myers, D. Weisenberger, R. Penny, R. Kucherlapati, C. Perou, D. Hayes, R. Gibbs, M. Marra, G. Mills, E. Lander, P. Spellman, R. Wilson, C. Sander, J. Weinstein, M. Meyerson, S. Gabriel, P. Laird, D. Haussler, G. Getz, L. Chin (2013)
The Somatic Genomic Landscape of GlioblastomaCell, 155
Genomic alterations are critical for the diagnosis, prognostication, and treatment of patients with infiltrating gliomas. Telomerase reverse transcriptase promoter (TERTp) mutations are among such crucial alterations. Although DNA sequencing is the preferred method for identifying TERTp mutations, it has limitations related to cost and accessibility. We tested telomerase reverse transcriptase (TERT) immunohistochemistry (IHC) as a surrogate for TERTp mutations in infiltrating gliomas. Thirty-one infiltrating gliomas were assessed by IHC using an anti-TERT Y182 antibody. IHC results were analyzed by a board-certified neuropathologist. Tumors were analyzed by targeted next-generation sequencing. A literature review of the use of TERT antibodies as a surrogate for TERTp mutations was performed. Eighteen gliomas harbored TERTp mutations. Overall, TERT IHC demonstrated a sensitivity of 61.1% and a specificity of 69.2% for identifying TERTp mutations. Among the 19 IDH1/IDH2-wild-type gliomas, 16 (84%) harbored TERTp mutations, and TERT IHC had a sensitivity of 62.5% and a specificity of 33.3%. Among the 12 IDH1/IDH2-mutant gliomas, 2 (17%) harbored TERTp mutations, and TERT IHC had a sensitivity of 50% and a specificity of 80%. TERT IHC had low positive and negative likelihood values in the identification of TERTp mutations. The literature review included 5 studies with 645 patients and 4 different TERT antibodies. The results consistently showed poor sensitivity and specificity of TERT IHC for identifying TERTp mutations. TERT IHC is a suboptimal surrogate marker for TERTp mutations in infiltrating gliomas. The need remains for cost-effective, efficient, and accessible alternatives to next-generation sequencing for the evaluation of TERTp mutations in gliomas.
Applied Immunohistochemistry – Wolters Kluwer Health
Published: May 24, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.